Abstract
Introduction Prisons are susceptible to outbreaks. Control measures focusing on isolation and cohorting negatively affect wellbeing. We present an outbreak of COVID-19 in a large male prison in Wales, UK, October 2020 to April 2021, and discuss control measures.
Methods We gathered case-information, including demographics, staff-residence postcode, resident cell number, work areas/dates, test results, staff interview dates/notes and resident prison-transfer dates. Epidemiological curves were mapped by prison location. Control measures included isolation (exclusion from work or cell-isolation), cohorting (new admissions and work-area groups), asymptomatic testing (case-finding), removal of communal dining and movement restrictions. Facemask use and enhanced hygiene were already in place. Whole genome sequencing (WGS) and interviews determined genetic relationship between cases plausibility of transmission.
Results Of 453 cases, 53% (n=242) were staff, most aged 25-34 years (11.5% females, 27.15% males) and symptomatic (64%). Crude attack-rate was higher in staff (29%, 95%CI: 26-64%) than in residents (12%, 95%CI: 9-15%).
Conclusions Whole genome sequencing can help differentiate multiple introductions from person-to-person transmission in prisons. It should be introduced alongside asymptomatic testing as soon as possible to control prison outbreaks. Timely epidemiological investigation, including data visualisation, allowed dynamic risk assessment and proportionate control measures, minimising reduction in resident welfare.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No additional funding was received to undertake the outbreak investigation; outbreaks represent part of the core duties of the Public Health Wales Health Protection Division. The sequencing of samples was funded by Welsh Government and as part of the COVID-19 Genomics UK Consortium (COG-UK). COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute. Analysis of genome sequenced samples was performed using the MRC CLIMB platform [grant reference MR/L015080/1].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical oversight of the project was provided by the PHW Research and Development Division (supplementary information). As this work was carried out as part of the health protection response to a public health emergency in Wales, using routinely collected surveillance data, PHW Research and Development Division advised that NHS research ethics approval was not required. The use of named patient data in the investigation of communicable disease outbreaks and surveillance of notifiable disease is permitted under PHW Establishment Order. Data were held and processed under PHW information governance arrangements, in compliance with the Data Protection Act, Caldicott Principles and PHW guidance on the release of small numbers. No data identifying protected characteristics of an individual were released outside of the OCT.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this investigation contain personal identifiable information of a vulnerable population. Anonymised information, including that contained in the supplementary information, required to reproduce these results is available from the corresponding author on reasonable request.
